These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 24853893)

  • 1. DPP-4 inhibitors-renoprotection in diabetic nephropathy?
    Panchapakesan U; Pollock CA
    Diabetes; 2014 Jun; 63(6):1829-30. PubMed ID: 24853893
    [No Abstract]   [Full Text] [Related]  

  • 2. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen.
    Kanasaki K; Shi S; Kanasaki M; He J; Nagai T; Nakamura Y; Ishigaki Y; Kitada M; Srivastava SP; Koya D
    Diabetes; 2014 Jun; 63(6):2120-31. PubMed ID: 24574044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological and clinical profiles of the DPP-4 inhibitor linagliptin (Trazenta)].
    Ohmura T; Hayashi N; Encinas J
    Nihon Yakurigaku Zasshi; 2012 Apr; 139(4):174-83. PubMed ID: 22498683
    [No Abstract]   [Full Text] [Related]  

  • 4. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.
    Alter ML; Ott IM; von Websky K; Tsuprykov O; Sharkovska Y; Krause-Relle K; Raila J; Henze A; Klein T; Hocher B
    Kidney Blood Press Res; 2012; 36(1):119-30. PubMed ID: 23171828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice.
    Schürmann C; Linke A; Engelmann-Pilger K; Steinmetz C; Mark M; Pfeilschifter J; Klein T; Frank S
    J Pharmacol Exp Ther; 2012 Jul; 342(1):71-80. PubMed ID: 22493041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice.
    Darsalia V; Olverling A; Larsson M; Mansouri S; Nathanson D; Nyström T; Klein T; Sjöholm Å; Patrone C
    Regul Pept; 2014 May; 190-191():25-31. PubMed ID: 24821550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury.
    Terawaki Y; Nomiyama T; Kawanami T; Hamaguchi Y; Takahashi H; Tanaka T; Murase K; Nagaishi R; Tanabe M; Yanase T
    Cardiovasc Diabetol; 2014 Nov; 13():154. PubMed ID: 25407968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype rats.
    Retlich S; Withopf B; Greischel A; Staab A; Jaehde U; Fuchs H
    Biopharm Drug Dispos; 2009 Nov; 30(8):422-36. PubMed ID: 19771584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
    Graefe-Mody EU; Padula S; Ring A; Withopf B; Dugi KA
    Curr Med Res Opin; 2009 Aug; 25(8):1963-72. PubMed ID: 19552619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Tiwari A
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1091-104. PubMed ID: 19777398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hibiscus sabdariffa polyphenols alleviate insulin resistance and renal epithelial to mesenchymal transition: a novel action mechanism mediated by type 4 dipeptidyl peptidase.
    Peng CH; Yang YS; Chan KC; Wang CJ; Chen ML; Huang CN
    J Agric Food Chem; 2014 Oct; 62(40):9736-43. PubMed ID: 25226384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition.
    Kröller-Schön S; Knorr M; Hausding M; Oelze M; Schuff A; Schell R; Sudowe S; Scholz A; Daub S; Karbach S; Kossmann S; Gori T; Wenzel P; Schulz E; Grabbe S; Klein T; Münzel T; Daiber A
    Cardiovasc Res; 2012 Oct; 96(1):140-9. PubMed ID: 22843705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2012 Feb; 67(2):91-7. PubMed ID: 22482239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dipeptidyl peptidase-4 inhibitor linagliptin exhibits time- and dose-dependent localization in kidney, liver, and intestine after intravenous dosing: results from high resolution autoradiography in rats.
    Greischel A; Binder R; Baierl J
    Drug Metab Dispos; 2010 Sep; 38(9):1443-8. PubMed ID: 20538719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux.
    Fuchs H; Runge F; Held HD
    Eur J Pharm Sci; 2012 Apr; 45(5):533-8. PubMed ID: 22198311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of highly potent DPP-4 inhibitors by hybrid compound design based on linagliptin and alogliptin.
    Lai ZW; Li C; Liu J; Kong L; Wen X; Sun H
    Eur J Med Chem; 2014 Aug; 83():547-60. PubMed ID: 24996141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity.
    Yamagishi S; Ishibashi Y; Ojima A; Sugiura T; Matsui T
    Int J Cardiol; 2014 Sep; 176(2):550-2. PubMed ID: 25065332
    [No Abstract]   [Full Text] [Related]  

  • 19. Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis.
    Nakashima S; Matsui T; Takeuchi M; Yamagishi SI
    Horm Metab Res; 2014 Sep; 46(10):717-21. PubMed ID: 24710699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice.
    Jelsing J; Vrang N; van Witteloostuijn SB; Mark M; Klein T
    J Endocrinol; 2012 Sep; 214(3):381-7. PubMed ID: 22761275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.